Kristen Oelschlager Sells 8,586 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.77, for a total value of $255,605.22. Following the completion of the sale, the chief operating officer directly owned 13,288 shares of the company’s stock, valued at approximately $395,583.76. This represents a 39.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $30.47 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The stock’s fifty day moving average is $23.55 and its two-hundred day moving average is $26.16. The firm has a market capitalization of $930.86 million, a P/E ratio of -46.17 and a beta of 0.98. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The business had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. On average, research analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

CSTL has been the topic of a number of analyst reports. Roth Capital began coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price on the stock. KeyCorp set a $35.00 price target on shares of Castle Biosciences in a research note on Friday, May 29th. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a report on Friday, July 31st. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Key Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
• Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
• Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Truist Financial Corp lifted its holdings in shares of Castle Biosciences by 1.1% during the fourth quarter. Truist Financial Corp now owns 23,628 shares of the company’s stock worth $919,000 after purchasing an additional 257 shares during the period. Harbor Capital Advisors Inc. grew its position in Castle Biosciences by 2.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 13,432 shares of the company’s stock valued at $523,000 after buying an additional 261 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Castle Biosciences by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares during the period. CWM LLC increased its stake in Castle Biosciences by 20.5% in the 4th quarter. CWM LLC now owns 2,302 shares of the company’s stock valued at $90,000 after buying an additional 391 shares during the period. Finally, HRT Financial LP raised its position in Castle Biosciences by 0.9% during the 4th quarter. HRT Financial LP now owns 47,654 shares of the company’s stock worth $1,853,000 after buying an additional 415 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.